The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia

Abstract

PurposeThe purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD).MethodsThe Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA). Infants in the case group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was defined as the start time of the study.ResultsThe incidence of moderate to severe BPD was not different between the groups (case group: 13 of 30 [43.3%] vs. control group: 19 of 36 [52.8%], P=0.912). Additionally, secondary outcomes such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly different. There were no serious adverse drug reactions in either group, and furthermore the rate of occurrence of mild drug related-events were not significantly different (case group: 10 of 42 [23.8%] vs. control group: 6 of 48 (15.8%), P=0.414).ConclusionMontelukast was not effective in reducing moderate or severe BPD. There were no significant adverse drug events associated with Montelukast treatment.

Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches

“…No difference was observed between the treated and untreated group in the rates of BPD or secondary respiratory outcomes. 113…”

Leukotriene B4mediates macrophage influx and pulmonary hypertension in bleomycin-induced chronic neonatal lung injury

“…Ex-premature infants with severe BPD also had increased urinary LTE 4 (10). Montelukast given as preventive therapy in at-risk preterm infants did not reduce the incidence of moderate-severe BPD (25); however, when employed as rescue therapy for severe late-stage BPD, it conferred a survival advantage (42). Increased cysLTs have also been reported in tracheal aspirates of infants with persistent PHT of the newborn, an acute form of PHT (48).…”

Effect of Montelukast on Bronchopulmonary Dysplasia (BPD) and Related Mechanisms

“…Moreover, studies have reported that montelukast has an activity of inhibiting the growth of tumor cells via inducing cell apoptosis [ 13 , 14 ]. Studies have also revealed the efficacy and safety of montelukast sodium in treating BPD [ 15 , 16 ], however, the precise role and underlying mechanism of montelukast in BPD development remain largely unclear.…”